Pantethine Eases Psoriasis Symptoms in 24-Patient Trial as Researchers Trace Inflammation to Cholesterol Metabolism
Updated
Updated · SciTechDaily · Nov 4
Pantethine Eases Psoriasis Symptoms in 24-Patient Trial as Researchers Trace Inflammation to Cholesterol Metabolism
3 articles · Updated · SciTechDaily · Nov 4
Summary
A 12-week trial in 24 psoriasis patients found Pantethine improved symptoms when added to standard topical treatment, with the strongest gains in participants who began with elevated cholesterol.
Chinese researchers linked that effect to Dendritic cells: high Vanin enzyme activity depleted pantethine, increased cholesterol buildup inside the cells and drove the immune overactivation behind psoriasis.
Mouse experiments reinforced the mechanism, showing that reducing Vanins or blocking them with a drug curbed dendritic-cell activity, prevented psoriasis development and eased symptoms after pantethine treatment.
Pantethine is already sold as a vitamin B5 derivative used to lower cholesterol, but the authors said the human data are only proof of concept and do not establish it as a standalone psoriasis therapy.
The study points to a broader Vanin-pantethine-cholesterol pathway that could become a target for psoriasis and other dendritic cell-mediated autoimmune diseases.